---
schema_version: "secwatch.filing_event.v1"
accession: "0001935979-26-000048"
form_type: "8-K"
ticker: "BHVN"
cik: "0001935979"
company_name: "Biohaven Ltd."
filed_at: "2026-05-27T21:13:33+00:00"
generated_at: "2026-05-27T21:19:35.305862+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# Biohaven reports positive clinical data for opakalim in epilepsy and BHV-1300/BHV-1400 in autoimmune diseases at R&D Day

## Summary
- Opakalim 75 mg prolonged median time to second seizure to 141 days vs 47 days for placebo in idiopathic generalized epilepsy trial.
- 54% of focal epilepsy patients on opakalim achieved ≥50% seizure reduction over six months in open-label extension.
- BHV-1300 reduced pathogenic TSHR-IgG1 >80% by week 12 and normalized thyroid hormones within weeks in Graves' disease patients.
- BHV-1400 reduced Gd-IgA1 >60% within hours and 70% within one month in IgA nephropathy, with early eGFR and UPCR improvements.
- Both degrader programs showed well-tolerated safety profiles with no serious adverse events; pivotal Phase 3 trials expected to initiate mid-2026.

## SEC filing metadata
- accession: 0001935979-26-000048
- form_type: 8-K
- ticker: BHVN
- cik: 0001935979
- company_name: Biohaven Ltd.
- filed_at: 2026-05-27T21:13:33+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1935979/000193597926000048/0001935979-26-000048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1935979/000193597926000048/bhvn-20260526.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001935979-26-000048
- JSON: https://secwatch.observer/filing/0001935979-26-000048.json
- Plain text: https://secwatch.observer/filing/0001935979-26-000048.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.